Rosetta Genomics this week announced that it has generated preliminary data showing that blood-based microRNAs can be used to identify and stratify heart failure patients.
The company did not, however, provide specific details regarding the miRNAs themselves.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
